Utility of a prognostic scoring system for allogeneic stem cell transplantation in patients with chronic myeloid leukemia

Acta Haematologica

Volumn 109, Issue 3, 2003, Pages 119-123

  Qazilbash, Muzaffar H ^a   Devetten, Marcel P ^a   Abraham, Jame ^a   Lynch, Joseph P ^a   Beall, Charles L ^a   Weisenborn, Robin ^a   Bunner, Pam ^a   Ericson, Solveig G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogeneic stem cell transplantation; Chronic myelogenous leukemia; Prognostic scoring system; Risk score

Indexed keywords

ADULT; ALLOGENEIC RESTRICTION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DATA ANALYSIS; DISEASE DURATION; FEMALE; HIGH RISK POPULATION; HUMAN; KAPLAN MEIER METHOD; LIVING DONOR; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 0037276239     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069283     Document Type: Article

References (24)

1. Talpaz M, Kantarjian HM, Kurzrock R, Trujillo JM, Gutterman JU: Interferon alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 1991;114:532-538.
2. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myelogenous leukemia. N Engl J Med 1994;330:820-825.
3. Guilhot F, Chastang C, Michallet M, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall IF, Tanzer L: Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997;337:223-229.
4. Druker BJ, Sawyers CL, Kantarjian H, Reese SF, Ford JM, Capdeville R, Talpaz M: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
6. Childs R, Epperson D, Bahceci E, Clave E, Barrett J: Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: In vivo and in vitro evidence for a graft-versus-leukaemia effect. Br J Haematol 1999;107:396-400.
7. Goldman IM, Druker BJ: Chronic myeloid leukemia: Current treatment options. Blood 2001;98:2039-2042.
8. Miyamura K, Barrett AJ, Kodera Y, Saito H: Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: A review of recent results. Bone Marrow Transplant 1994;14:201-209.
9. Collins RH Jr, Pineiro LA, Nemunaitis JJ, Jain VK, Waxman D, Miller WV, Fay JW: Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation. Transfusion 1995;35:891-898.
10. McGlave P, Arthur D, Haake R, Hurd D, Miller W, Vercellotti G, Weisdorf D, Kim T, Ramsay N, Kersey J: Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation. J Clin Oncol 1987;5:1033-1040.
11. Gratwohl A, Hermans J, Niederwieser D, Frassoni F, Arcese W, Gahrton G, Bandini G, Carreras E, Vernant JP, Bosi A, Dewitte T, Fibbe WE, Zwaan F, Michallet M, Ruutu T, Devergie A, Iriondo A, Apperley J, Reiffers J, Speck B, Goldman J: Bone marrow transplantation for chronic myeloid leukemia: Long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1993;12:509-516.
12. Snyder DS, Negrin RS, O'Donnell MR, Chao NJ, Amylon MD, Long GD, Nademanee AP, Stein AS, Parker PM, Smith EP, Somlo G, Margolin K, Molina A, Stepan DE, Lipsett JA, Hoppe RT, Slovak ML, Niland JC, Dagis AC, Wong RM, Forman SJ, Blume KG: Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. Blood 1994;84:1672-1679.
13. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, Ruutu T, Vemant JP, de Witte T, Apperley J: Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998;352:1087-1092.
14. Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, Buckner CD, Cheever MA, Deeg HJ, Doney K, Flournoy N, Greenberg P, Hansen JA, Martin P, McGuffin R, Ramberg R, Sanders JE, Singer J, Stewart P, Storb R, Sullivan K, Weiden PL, Witherspoon R: Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986;104:155-163.
15. Bacigalupo A, Gualandi F, Van Lint MT, Sessarego M, Frassoni F, Occhini D, Lamparelli T, Oneto R, Vitale V, Corvo R, Delatorre ER, Marmont AM: Multivariate analysis of risk factors for survival and relapse in chronic granulocytic leukemia following allogeneic marrow transplantation: Impact of disease related variables (Sokal score). Bone Marrow Transplant 1993;12:443-448.
16. McGlave P: Bone marrow transplants in chronic myelogenous leukemia: An overview of determinants of survival. Semin Hematol 1990;27(3 suppl 4):23-30.
17. Clift RA, Buckner CD, Thomas ED, Bryant E, Anasetti C, Bensinger WI, Bowden R, Deeg HJ, Doney KC, Fisher LD, Hansen JA, Martin P, McDonald GB, Sanders JE, Schoch G, Singer J, Storb R, Sullivan KM, Witherspoon RP, Appelbaum FR: Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood 1994;84:4368-4373.
18. Devergie A, Apperley J, Labopin M, Madrigal A, Jacobsen N, Carreras E, Prentice HG, Jouet JP, Kolb HJ, Herstenstein B, Bacigalupo A, Evensen SA, Ljungman P, de Witte T, Reiffers J, Nagler A, Clark RE, Goldman JM, Gratwohl A: European results of matched unrelated transplantation for chronic myeloid leukemia: Impact of class II mismatching. Bone Marrow Transplant 1997;20:11-19.
19. Sierra J, Storer B, Hansen JA, Bjerke JW, Martin PJ, Petersdorf EW, Appelbaum FR, Bryant E, Chauncey TR, Sale G, Sanders JE, Storb R, Sullivan KM, Anasetti C: Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: The effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997;89:4226-4235.
20. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA: Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338:962-968.
21. Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave PB, Messner HA, Weiner RS, Rimm AA: Allogeneic bone marrow transplantation for chronic myelogenous leukemia. Lancet 1984;i:665-668.
22. Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD: Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic transplantation. Blood 1992;80:1358.
23. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
24. Passweg J, Walker I, Sobocinski K, Rio B, Litzow M, Giralt S, Carreras E, Szydlo R, Bolwell B, Ilhan O, Seiter K, Maharaj D, Pasquini R, Carabasi M, Kolb H, Gale R, Schouten H, Cornelissen J, Goldman J, Gratwohl A, Klein J, Horowitz M: Validation of the EBMT risk score for recipients of allogeneic hematopoietic stem cell transplants for chronic myeloid leukemia (CML). Blood Suppl 2001;98:1470a.